Ronald Ellis is a Neurology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics need a complete publication history and a confident author match. We omit them when either check fails. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
- Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV
Sponsor: University of California, San Diego
- Phase II Trial of Tesamorelin for Cognition in Aging HIV-Infected Persons
Sponsor: University of California, San Diego
- Clinical Trial of CNS-targeted HAART (CIT2)
Sponsor: University of California, San Diego
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
1 company reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- TheratechnologiesProgram year20222 paymentsResearch$22,402openpaymentsdata.cms.gov ↗
- Sunovion Pharmaceuticals Inc.Program year20211 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
90.5%N-methyl-D-aspartate Receptor Antagonist31%Memantine Hcl100%Part D<11 patientsGabapentinoids19.8%Pregabalin52%Gabapentin48%Part D<11 patients+ 3 more classes in this area
Musculoskeletal
9.5%Nonsteroidal Anti-inflammatory Drug9.5%Indomethacin100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
16 NIH research awards on record, funded 1999–2026 per NIH RePORTER. The latest:
- CHARTER Plus: A resource for cutting-edge research on neurological function and mental health in people with HIV and substance use disorders across the lifespan
University of California, San Diego
FY2026$1,965,319R24MH129166 - Epigenetics of the neuroimmune axis in HIV and cannabis use
University of California, San Diego
FY2026$1,233,586R01DA066096
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
No other directory profiles share this institution yet.
Bruce Miller, MD
University of California, San Francisco (UCSF)
Brett Kissela, MD
Medical College of Wisconsin
Richard Lipton, MD
Albert Einstein College of Medicine
Bradley Boeve, MD
Mayo Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”